MRI multicentre prospective survey in thalassaemia major patients treated with deferasirox versus deferiprone and desferrioxamine

We prospectively assessed the efficacy of deferasirox versus deferiprone or desferrioxamine as monotherapy in thalassaemia major (TM) patients by magnetic resonance imaging (MRI). We selected the patients enrolled in the Myocardial Iron Overload in Thalassaemia network who received only one chelator between two MRIs (deferasirox = 235, deferiprone = 142, desferrioxamine = 162). Iron overload was measured by T2* technique and biventricular function by cine images. Among the patients with baseline myocardial iron, in all three groups there was a significant improvement in global heart T2* values. The deferiprone and desferrioxamine groups showed a significant improvement in left ventricular ejection fraction (LVEF). Only the deferiprone group showed a significant improvement in right ventricular ejection fraction (RVEF). The improvement in global heart T2* was significantly lower in the deferasirox versus the deferiprone group. The improvement in the LVEF was significantly higher in the deferiprone and desferrioxamine groups than in the deferasirox group and the improvement in the RVEF was significantly higher in the deferiprone than in deferasirox group. Among the patients with baseline hepatic iron, the changes in hepatic iron were comparable in deferasirox versus the other groups. Deferasirox monotherapy was less effective than deferiprone in improving myocardial siderosis and biventricular function and less effective than desferrioxamine in improving the LVEF.

[1]  V. Positano,et al.  Prediction of cardiac complications for thalassemia major in the widespread cardiac magnetic resonance era: a prospective multicentre study by a multi-parametric approach , 2018, European heart journal cardiovascular Imaging.

[2]  Lorenzo Monti,et al.  Reference values of cardiac volumes, dimensions, and new functional parameters by MR: A multicenter, multivendor study , 2017, Journal of magnetic resonance imaging : JMRI.

[3]  V. Positano,et al.  Multiparametric Cardiac Magnetic Resonance Survey in Children With Thalassemia Major: A Multicenter Study , 2015, Circulation. Cardiovascular imaging.

[4]  D. Pennell,et al.  Sustained improvements in myocardial T2* over 2 years in severely iron‐overloaded patients with beta thalassemia major treated with deferasirox or deferoxamine , 2015, American journal of hematology.

[5]  V. Positano,et al.  Different patterns of myocardial iron distribution by whole-heart T2* magnetic resonance as risk markers for heart complications in thalassemia major. , 2014, International journal of cardiology.

[6]  M. D. de Jonge,et al.  Mapping iron in human heart tissue with synchrotron x-ray fluorescence microscopy and cardiovascular magnetic resonance , 2014, Journal of Cardiovascular Magnetic Resonance.

[7]  D. Pennell,et al.  A 1-year randomized controlled trial of deferasirox vs deferoxamine for myocardial iron removal in β-thalassemia major (CORDELIA). , 2014, Blood.

[8]  M. Kew.  Hepatic Iron Overload and Hepatocellular Carcinoma , 2014, Liver Cancer.

[9]  D. Pennell,et al.  Cardiovascular function and treatment in β-thalassemia major: a consensus statement from the American Heart Association. , 2013, Circulation.

[10]  H. Rienhoff,et al.  The use of appropriate calibration curves corrects for systematic differences in liver R2* values measured using different software packages , 2013, British journal of haematology.

[11]  V. Positano,et al.  Cardiac and hepatic iron and ejection fraction in thalassemia major: Multicentre prospective comparison of combined Deferiprone and Deferoxamine therapy against Deferiprone or Deferoxamine Monotherapy , 2013, Journal of Cardiovascular Magnetic Resonance.

[12]  D. Pennell,et al.  Deferasirox for up to 3 years leads to continued improvement of myocardial T2* in patients with β-thalassemia major , 2012, Haematologica.

[13]  Dudley J Pennell,et al.  On T2* Magnetic Resonance and Cardiac Iron , 2011, Circulation.

[14]  V. Positano,et al.  Cardiac iron and cardiac disease in males and females with transfusion-dependent thalassemia major: a T2* magnetic resonance imaging study , 2011, Haematologica.

[15]  V. Positano,et al.  Left Ventricular Volumes, Mass and Function normalized to the body surface area, age and gender from CMR in a large cohort of well-treated Thalassemia Major patients without myocardial iron overload , 2011, Journal of Cardiovascular Magnetic Resonance.

[16]  V. Positano,et al.  Right Ventricular Volumes and Function normalized to body surface area, age and sex in a large cohort of well-treated Thalassemia Major without myocardial iron overload , 2011, Journal of Cardiovascular Magnetic Resonance.

[17]  Massimo Lombardi,et al.  Single region of interest versus multislice T2* MRI approach for the quantification of hepatic iron overload , 2011, Journal of magnetic resonance imaging : JMRI.

[18]  Massimo Midiri,et al.  Deferasirox, Deferiprone and Desferrioxamine Treatment in Thalassemia Major Patients: Cardiac Iron and Function Comparison Determined by Quantitative Magnetic Resonance Imaging Early Release Paper Deferasirox, Deferiprone and Desferrioxamine Treatment in Thalassemia Major Patients: Cardiac Iron and , 2022 .

[19]  V. Berdoukas,et al.  In search of the optimal iron chelation therapy for patients with thalassemia major , 2011, Haematologica.

[20]  P. Ricchi,et al.  Combined chelation therapy in thalassemia major with deferiprone and desferrioxamine: a retrospective study , 2010, European journal of haematology.

[21]  V. Positano,et al.  Preferential patterns of myocardial iron overload by multislice multiecho T*2 CMR in thalassemia major patients , 2010, Magnetic resonance in medicine.

[22]  D. Pennell,et al.  Efficacy of deferasirox in reducing and preventing cardiac iron overload in beta-thalassemia. , 2010, Blood.

[23]  A. Taher,et al.  Deferasirox (Exjade®) significantly improves cardiac T2* in heavily iron-overloaded patients with β-thalassemia major , 2008, Annals of Hematology.

[24]  Luigi Landini,et al.  Evaluation of a web-based network for reproducible T2* MRI assessment of iron overload in thalassemia , 2009, Int. J. Medical Informatics.

[25]  Massimo Midiri,et al.  Multislice multiecho T2* cardiac magnetic resonance for the detection of heterogeneous myocardial iron distribution in thalassaemia patients , 2009, NMR in biomedicine.

[26]  Massimo Midiri,et al.  Multicenter validation of the magnetic resonance t2* technique for segmental and global quantification of myocardial iron , 2009, Journal of magnetic resonance imaging : JMRI.

[27]  Massimo Midiri,et al.  Improved T2* assessment in liver iron overload by magnetic resonance imaging. , 2009, Magnetic resonance imaging.

[28]  T. Coates,et al.  Longitudinal analysis of heart and liver iron in thalassemia major. , 2008, Blood.

[29]  Matthew W. Darlison,et al.  Improved survival of thalassaemia major in the UK and relation to T2* cardiovascular magnetic resonance , 2008, Journal of cardiovascular magnetic resonance : official journal of the Society for Cardiovascular Magnetic Resonance.

[30]  Massimo Midiri,et al.  Standardized T2* map of normal human heart in vivo to correct T2* segmental artefacts , 2007, NMR in biomedicine.

[31]  D. Pennell,et al.  A Randomized, Placebo-Controlled, Double-Blind Trial of the Effect of Combined Therapy With Deferoxamine and Deferiprone on Myocardial Iron in Thalassemia Major Using Cardiovascular Magnetic Resonance , 2007, Circulation.

[32]  Mark A Westwood,et al.  Randomized controlled trial of deferiprone or deferoxamine in beta-thalassemia major patients with asymptomatic myocardial siderosis. , 2006, Blood.

[33]  V. Positano,et al.  Multislice multiecho T2* cardiovascular magnetic resonance for detection of the heterogeneous distribution of myocardial iron overload , 2006, Journal of magnetic resonance imaging : JMRI.

[34]  V. Positano,et al.  Evaluation of the efficacy of oral deferiprone in β‐thalassemia major by multislice multiecho T2* , 2006, European journal of haematology.

[35]  T. Coates,et al.  MRI R2 and R2* mapping accurately estimates hepatic iron concentration in transfusion-dependent thalassemia and sickle cell disease patients. , 2005, Blood.

[36]  D. Pennell,et al.  A single breath‐hold multiecho T2* cardiovascular magnetic resonance technique for diagnosis of myocardial iron overload , 2003, Journal of magnetic resonance imaging : JMRI.

[37]  D. Pennell,et al.  Comparison of effects of oral deferiprone and subcutaneous desferrioxamine on myocardial iron concentrations and ventricular function in beta-thalassaemia , 2002, The Lancet.

[38]  M. Cerqueira,et al.  Standardized myocardial segmentation and nomenclature for tomographic imaging of the heart: A statement for healthcare professionals from the Cardiac Imaging Committee of the Council on Clinical Cardiology of the American Heart Association , 2002, The international journal of cardiovascular imaging.

[39]  M. Cerqueira,et al.  Standardized myocardial segmentation and nomenclature for tomographic imaging of the heart. A statement for healthcare professionals from the Cardiac Imaging Committee of the Council on Clinical Cardiology of the American Heart Association. , 2002, Circulation.

[40]  D N Firmin,et al.  Cardiovascular T2-star (T2*) magnetic resonance for the early diagnosis of myocardial iron overload. , 2001, European heart journal.

[41]  C. McLaren,et al.  Hepatic iron concentration and total body iron stores in thalassemia major. , 2000, The New England journal of medicine.

[42]  A. Cnaan,et al.  Survival and complications in patients with thalassemia major treated with transfusion and deferoxamine. , 2004, Haematologica.

[43]  D. Pennell,et al.  Comparison of effects of oral deferiprone and subcutaneous desferrioxamine on myocardial iron concentrations and ventricular function in beta-thalassaemia ☆ , 2003 .